M. Felsinger

Prognostic Impact of PD‐L1 Expression in Ovarian Cancer: Analysis of a Real‐World Cohort Treated With Primary Platinum‐Based Chemotherapy

Programmed death‐ligand 1 (PD‐L1) has emerged as a potential biomarker for prognosis and treatment response in various solid tumors. However, its clinical relevance in ovarian carcinoma (OC) remains unclear, with published studies reporting inconsistent associations with platinum sensitivity and survival. These discrepancies are likely related to the biological heterogeneity of OC and methodological variability in PD‐L1 evaluation. In the absence of a standardized, OC‐specific assessment methodology, the Combined Positive Score (CPS) with cutoffs of ≥ 1 and ≥ 10, applied in other tumor types, represents a pragmatic approach.